KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Interest & Investment Income: 2009-2024

Historic Interest & Investment Income for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $2.1 million.

  • Rigel Pharmaceuticals' Interest & Investment Income rose 157.41% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year increase of 31.67%. This contributed to the annual value of $2.1 million for FY2024, which is 7.92% down from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported Interest & Investment Income of $2.1 million as of FY2024, which was down 7.92% from $2.3 million recorded in FY2023.
  • Over the past 5 years, Rigel Pharmaceuticals' Interest & Investment Income peaked at $2.3 million during FY2023, and registered a low of $47,000 during FY2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $2.1 million (2024), whereas its average is $1.7 million.
  • In the last 5 years, Rigel Pharmaceuticals' Interest & Investment Income plummeted by 91.92% in 2021 and then skyrocketed by 1,355.32% in 2022.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Interest & Investment Income stood at $582,000 in 2020, then tumbled by 91.92% to $47,000 in 2021, then skyrocketed by 1,355.32% to $684,000 in 2022, then skyrocketed by 232.16% to $2.3 million in 2023, then decreased by 7.92% to $2.1 million in 2024.